Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette–Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer

A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette–Guérin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion(®...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Med Oncol
Hlavní autoři: Liem, Esmee I. M. L., Baard, Joyce, Cauberg, Evelyne C. C., Bus, Mieke T. J., de Bruin, D. Martijn, Laguna Pes, M. Pilar, de la Rosette, Jean J. M. C. H., de Reijke, Theo M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2017
Témata:
Original Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581817/
https://ncbi.nlm.nih.gov/pubmed/28866819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-1033-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky